Issue link: http://clhia.uberflip.com/i/406567
33 This process should explicitly include public and private payers, pharmaceutical manufacturers, health care professionals (e.g., physicians) and patient groups. All stakeholder groups have a vested interest in working to design a robust approval and funding system that will be sustainable in the long-term and we believe that such a system will only be sustainable if it is designed collaboratively with all stakeholders. THEREFORE, THE CLHIA RECOMMENDS THAT: • GOVERNMENTS LEAD THE WORK TOWARDS CREATING A NEW END-TO-END APPROVAL PROCESS FOR ORPHAN DRUGS THAT WILL INCLUDE NOT ONLY A SAFETY AND EFFECTIVENESS REVIEW BUT ALSO WORK TO ESTABLISH AN EQUITABLE AND SUSTAINABLE FUNDING ARRANGEMENT FOR SUCH DRUGS AND THAT THE REVIEW PROCESS SHOULD INCLUDE PUBLIC AND PRIVATE PAYERS , DRUG MANUFACTURERS, HEALTH CARE PROFESSIONALS, AND PATIENTS GROUPS. 4. CONCLUSION & PRIORITIES FOR REFORM The current system of pharmacare must be fundamentally reformed if it is to serve Canadians well in the long-term. This paper presents actionable recommendations to governments on a wide range of reforms that will help address the key gaps and sustainability challenges of the current system. While all of the recommendations in this paper need to be addressed over the medium term, as a priority, the industry believes that reform should be undertaken as follows: • Reform the Patented Medicine Prices Review Board's mandate and practices in order to achieve lower prices for all Canadians;